BOSTON, MA -- September 19, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, announced today an expanded long-term supplier and co-marketing agreement that combines PerkinElmer’s versatile AlphaScreen® assay technology with TGR BioSciences’ SureFire™ cellular kinase assay kits. The collaboration combines two highly advanced technologies that permit rapid and accurate screening of previously difficult targets through homogeneous non-radioactive measurement of phosphorylated full length proteins.

“The combination of our highly sensitive AlphaScreen technology with TGR’s SureFire cellular kinase assays will enable researchers to easily screen a number of key modulators of pathway activation in whole cells, which previously has been extremely difficult to accomplish,” said Dr. Richard Eglen, vice president and general manager, Discovery & Research Reagents, for PerkinElmer’s Life and Analytical Sciences division. “The signing of this agreement demonstrates PerkinElmer’s commitment to be a leader in enabling leading edge cell-based applications and tools for the Drug Discovery market.”

The expanded technology platform now includes six additional AlphaScreen SureFire cellular kinase assays, and can be used with many different cell lines, including primary cells, cells over-expressing cloned targets or cells expressing physiologically relevant endogenous levels of kinase or receptor target. These new kits offer novel cost effective methods for primary and secondary screening providing results in a more biologically applicable context.

The AlphaScreen SureFire cellular kinase assays represent key additions to the many applications built on PerkinElmer’s HTS-proven AlphaScreen technology, which is easily scalable to 384- and 1536-well microplate formats. These new assays will complement the existing AlphaScreen SureFire ERK assay kit which has been used successfully to screen for therapeutic modulators of both G-Protein Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) targets.

“We are already seeing significant interest and adoption of our first SureFire™ kit in the USA and Europe, and we anticipate a similar rapid growth of sales of the new kits”, says Dr. Leanna Read, Managing Director of TGR BioSciences. “The alliance with PerkinElmer on the world market provides both companies with important resources that complement their respective business models.”

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

About TGR BioSciences
TGR BioSciences Pty Ltd is a private biotechnology company based in Adelaide, South Australia. The company has developed leading-edge cell-based screening technology that is ideally suited to high throughput discovery. TGR markets its proprietary SureFire high throughput assay kit technology to biotechnology and pharmaceutical companies, and by offering bioactive discovery collaborations worldwide. Additional information is available through www.tgr-biosciences.com.au.